BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suhr OB, Larsson M, Ericzon BG, Wilczek HE. Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry. Transplantation. 2016;100:373-381. [PMID: 26656838 DOI: 10.1097/tp.0000000000001021] [Cited by in Crossref: 45] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Carroll A, Dyck PJ, de Carvalho M, Kennerson M, Reilly MM, Kiernan MC, Vucic S. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 2022;93:668-78. [PMID: 35256455 DOI: 10.1136/jnnp-2021-327909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years. Neurol Ther 2020;9:105-15. [PMID: 32107748 DOI: 10.1007/s40120-020-00180-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
3 Gertz MA, Mauermann ML, Grogan M, Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain Behav 2019;9:e01371. [PMID: 31368669 DOI: 10.1002/brb3.1371] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 14.3] [Reference Citation Analysis]
4 Iakovleva I, Begum A, Brännström K, Wijsekera A, Nilsson L, Zhang J, Andersson PL, Sauer-Eriksson AE, Olofsson A. Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer. PLoS One 2016;11:e0153529. [PMID: 27093678 DOI: 10.1371/journal.pone.0153529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
5 Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M. Heart transplantation in cardiac amyloidosis. Heart Fail Rev. 2017;22:317-327. [PMID: 28281017 DOI: 10.1007/s10741-017-9601-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
6 Mundayat R, Stewart M, Alvir J, Short S, Ong ML, Keohane D, Rill D, Sultan MB. Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther 2018;7:87-101. [PMID: 29633228 DOI: 10.1007/s40120-018-0097-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
7 Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis 2018;13:225. [PMID: 30558645 DOI: 10.1186/s13023-018-0947-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 González-Duarte A, Conceição I, Amass L, Botteman MF, Carter JA, Stewart M. Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy. Neurol Ther 2020;9:135-49. [PMID: 32232748 DOI: 10.1007/s40120-020-00183-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 2018;13:6. [PMID: 29343286 DOI: 10.1186/s13023-017-0726-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 11.5] [Reference Citation Analysis]
10 Zimmermann TS, Karsten V, Chan A, Chiesa J, Boyce M, Bettencourt BR, Hutabarat R, Nochur S, Vaishnaw A, Gollob J. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. Mol Ther 2017;25:71-8. [PMID: 28129130 DOI: 10.1016/j.ymthe.2016.10.019] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 17.2] [Reference Citation Analysis]
11 Yamashita T, Ueda M, Misumi Y, Masuda T, Nomura T, Tasaki M, Takamatsu K, Sasada K, Obayashi K, Matsui H, Ando Y. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol 2018;265:134-40. [PMID: 29177547 DOI: 10.1007/s00415-017-8640-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
12 Serrano D, Atzinger CB, Botteman MF. Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches. Neurol Ther 2018;7:141-54. [PMID: 29611130 DOI: 10.1007/s40120-018-0096-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Mnatsakanova D, Živković SA. Iatrogenic amyloid polyneuropathy after domino liver transplantation. World J Hepatol 2017; 9(3): 126-130 [PMID: 28217248 DOI: 10.4254/wjh.v9.i3.126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wange N, Anan I, Ericzon BG, Pennlert J, Pilebro B, Suhr OB, Wixner J. Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients. Transplantation. 2018;102:e59-e66. [PMID: 29019809 DOI: 10.1097/tp.0000000000001975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
15 Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol 2018;25:464-8. [PMID: 29115008 DOI: 10.1111/ene.13510] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
16 Adams D, Suhr OB, Dyck PJ, Litchy WJ, Leahy RG, Chen J, Gollob J, Coelho T. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 2017;17:181. [PMID: 28893208 DOI: 10.1186/s12883-017-0948-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 20.0] [Reference Citation Analysis]
17 Florian A, Bietenbeck M, Chatzantonis G, Hüsing-Kabar A, Schmidt H, Yilmaz A. Regression of cardiac amyloid load documented by cardiovascular magnetic resonance in a patient with hereditary amyloidosis. Clin Res Cardiol 2020;109:949-56. [PMID: 32048001 DOI: 10.1007/s00392-020-01611-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhao Y, Xin Y, Song Z, He Z, Hu W. Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis. J Clin Neurol 2019;15:108-15. [PMID: 30618225 DOI: 10.3988/jcn.2019.15.1.108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
19 Uneus EI, Wilhelmsson C, Bäckström D, Anan I, Wixner J, Pilebro B, Riklund K, Ögren M, Ögreen M, Axelsson J, Suhr OB, Sundström T. Cerebellar and Cerebral Amyloid Visualized by [18F]flutemetamol PET in Long-Term Hereditary V30M (p.V50M) Transthyretin Amyloidosis Survivors. Front Neurol 2022;13:816636. [DOI: 10.3389/fneur.2022.816636] [Reference Citation Analysis]
20 Vilatobá M, González-duarte A, Cruz-martínez R, García-juárez I, Leal-villalpando R. First two cases of domino liver transplantation in Mexico. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2022.05.003] [Reference Citation Analysis]
21 Theodorakakou F, Fotiou D, Dimopoulos MA, Kastritis E. Solid Organ Transplantation in Amyloidosis. Acta Haematol 2020;143:352-64. [PMID: 32535598 DOI: 10.1159/000508262] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Kerschen P, Planté-Bordeneuve V. Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy. Curr Treat Options Neurol 2016;18:53. [PMID: 27873215 DOI: 10.1007/s11940-016-0436-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
23 Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J, Alexander K, Masri A. Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review. Circ Genom Precis Med 2021;14:e003356. [PMID: 34461737 DOI: 10.1161/CIRCGEN.121.003356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Finsterer J, Iglseder S, Wanschitz J, Topakian R, Löscher WN, Grisold W. Hereditary transthyretin-related amyloidosis. Acta Neurol Scand 2019;139:92-105. [PMID: 30295933 DOI: 10.1111/ane.13035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
25 Nagano N, Muranaka A, Nishikawa R, Ohwada W, Kouzu H, Kamiyama N, Fujito T, Mochizuki A, Nagahara D, Nakanishi M, Ohkubo Y, Hisahara S, Nakao S, Katoh N, Ishikawa A, Sakurai A, Yano T. Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers: Case Series and Review of the Literature. Int Heart J 2022;63:168-75. [DOI: 10.1536/ihj.21-336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, Knebel F, Meder B, Morbach C, Nagel E, Schulze-Bahr E, Aus dem Siepen F, Frey N. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 2021;110:479-506. [PMID: 33459839 DOI: 10.1007/s00392-020-01799-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
27 Hikishima S, Sakai K, Akagi A, Yamaguchi H, Shibata S, Hayashi K, Nakano H, Kanemoto M, Usui Y, Taniguchi Y, Komatsu J, Nakamura-shindo K, Nozaki I, Hamaguchi T, Ono K, Iwasa K, Yamada M. Deterioration after Liver Transplantation and Transthyretin Stabilizer Administration in a Patient with ATTRv Amyloidosis with a Leu58Arg (p.Leu78Arg) <i>TTR</i> Variant. Intern Med . [DOI: 10.2169/internalmedicine.8945-21] [Reference Citation Analysis]